Pacira(US:PCRX) Globenewswire·2025-02-06 13:00Core Insights - Pacira BioSciences, Inc. has granted inducement awards to 15 new employees as part of its Amended and Restated 2014 Inducement Plan to encourage their employment with the company [1] - The inducement awards for new Chief Commercial Officer Brendan Teehan include a non-qualified stock option for 99,500 shares and a restricted stock unit award for 54,000 shares, both vesting over a period of time [2] - Chief Business Officer Krys Corbett received similar inducement awards, including a non-qualified stock option for 88,400 shares and a restricted stock unit award for 46,000 shares, also with a vesting schedule [3] - Additional awards were granted to four other employees for a total of 20,600 stock options and to 13 employees for 45,400 restricted stock units, all with a 10-year term and a four-year vesting schedule [4] - The vesting of these equity awards is contingent upon the employees' continued employment with Pacira [5] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº, aimed at transforming patient care [6] - EXPAREL is a long-acting local analgesic for postsurgical pain management, ZILRETTA is an extended-release injection for osteoarthritis knee pain, and ioveraº is a device for drug-free pain control [6] - The company is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [6]